Investigational drug · Phase 3
ABC008
Also called: Ulviprubart
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Inclusion Body Myositis (IBM), Inclusion Body Myositis, T-cell Large Granular Lymphocytic Leukemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
4
Any phase or sponsor naming "ABC008"
First trial start
2022
Sep 28, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABC008", any sponsor or status.
Conditions studied
As listed on its trial records.
- Inclusion Body Myositis (IBM)
- Inclusion Body Myositis
- T-cell Large Granular Lymphocytic Leukemia
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "ABC008" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body MyositisPivotal-lookingCompleted
Abcuro, Inc.Industry
NCT05721573 · 272 participants · Start Feb 28, 2023 · Primary completion Nov 6, 2025
Drug: ABC008 · For: Inclusion Body Myositis
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 45 sites in all
- Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body MyositisPivotal-lookingActive, not recruiting
Abcuro, Inc.Industry
NCT06450886 · 270 participants (planned) · Start Oct 21, 2024 · Primary completion Jan 2029
Drug: Ulviprubart (ABC008) · For: Inclusion Body Myositis (IBM)
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 21 sites in all
Abcuro, Inc.Industry
NCT05532722 · 21 participants · Start Sep 28, 2022 · Primary completion Aug 28, 2025
Drug: ABC008 · For: T-cell Large Granular Lymphocytic Leukemia
Sites: Duarte, California; Los Angeles, California; Boston, Massachusetts · 8 sites in all
Abcuro, Inc.Industry
NCT04659031 · 19 participants · Start May 25, 2021 · Primary completion Jan 10, 2025
Drug: ABC008 · For: Inclusion Body Myositis
Sites: Adelaide, Australia; Herston, Australia; Perth, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation.
Suzuki N, Izumi R, Ikeda K · Curr Opin Neurol 2026
- Isolation and Characterization of Novel Chlorella Species with Cold Resistance and High Lipid Accumulation for Biodiesel Production.
Koh HG, Kang NK, Kim EK, et al. · J Microbiol Biotechnol 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.